Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin

AAPS Journal

Volumn 19, Issue 6, 2017, Pages 1691-1702

  Aqil, Farrukh ^a,b   Munagala, Radha ^a,b   Jeyabalan, Jeyaprakash ^b   Agrawal, Ashish Kumar ^b   Gupta, Ramesh ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Anti cancer activity; Curcumin; Drug delivery; Exosomes; Toxicity

Indexed keywords

ACETONITRILE; ALCOHOL; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

A-549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CA SKI CELL LINE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG TOLERABILITY; DRUG UPTAKE; ENDOCYTOSIS; EXOSOME; FEEDING; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MDA-MB-231 CELL LINE; NCI-H1299 CELL LINE; NONHUMAN; PARTICLE SIZE; RAT; T-47D CELL LINE; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; ANIMAL; BIOAVAILABILITY; CHEMISTRY; MOUSE; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CURCUMIN; DRUG DELIVERY SYSTEMS; EXOSOMES; FEMALE; HUMANS; MICE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85031763228     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-017-0154-9     Document Type: Article

References (61)

1. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett. 2008;267(1):133–64. https://doi.org/10.1016/j.canlet.2008.03.025.
2. Bansal SS, Kausar H, Vadhanam MV, Ravoori S, Pan J, Rai SN, et al. Curcumin implants, not curcumin diet, inhibit estrogen-induced mammary carcinogenesis in ACI rats. Cancer Prev Res. 2014;7(4):456–65. https://doi.org/10.1158/1940-6207.CAPR-13-0248.
3. Zhongfa L, Chiu M, Wang J, Chen W, Yen W, Fan-Havard P, et al. Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol. 2012;69(3):679–89. https://doi.org/10.1007/s00280-011-1749-y.
4. Wang X, Wang Y, Chen ZG, Shin DM. Advances of cancer therapy by nanotechnology. Cancer Res Treat. 2009;41(1):1–11. https://doi.org/10.4143/crt.2009.41.1.1.
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–60. https://doi.org/10.1038/nrd1632.
6. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008;4(1):26–49. https://doi.org/10.1002/smll.200700595.
7. Donaldson K, Aitken R, Tran L, Stone V, Duffin R, Forrest G, et al. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci. 2006;92(1):5–22. https://doi.org/10.1093/toxsci/kfj130.
8. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol. 2007;150(5):552–8. https://doi.org/10.1038/sj.bjp.0707130.
9. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6. https://doi.org/10.1055/s-2006-957450.
10. Grill AE, Koniar B, Panyam J. Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin. Drug Deliv Transl Res. 2014;4(4):344–52. https://doi.org/10.1007/s13346-014-0199-6.
11. Aqil F, Jeyabalan J, Kausar H, Bansal SS, Sharma RJ, Singh IP, et al. Multi-layer polymeric implants for sustained release of chemopreventives. Cancer Lett. 2012;326(1):33–40. https://doi.org/10.1016/j.canlet.2012.07.017.
12. Gupta RC, Bansal SS, Aqil F, Jeyabalan J, Cao P, Kausar H, et al. Controlled-release systemic delivery—a new concept in cancer chemoprevention. Carcinogenesis. 2012;33(8):1608–15. https://doi.org/10.1093/carcin/bgs209.
13. Bansal SS, Kausar H, Aqil F, Jeyabalan J, Vadhanam MV, Gupta RC, et al. Curcumin implants for continuous systemic delivery: safety and biocompatibility. Drug Deliv Transl Res. 2011;1(4):332–41. https://doi.org/10.1007/s13346-011-0028-0.
14. Yokoyama M. Polymeric micelles as drug carriers: their lights and shadows. J Drug Target. 2014;22(7):576–83. https://doi.org/10.3109/1061186X.2014.934688.
15. Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016;6(4):287–96. https://doi.org/10.1016/j.apsb.2016.02.001.
16. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine. 2012;7:1525–41. https://doi.org/10.2147/IJN.S29661ijn-7-1525.
17. Lakhal S, Wood MJ. Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. BioEssays. 2011;33(10):737–41. https://doi.org/10.1002/bies.201100076.
18. Aqil F, Kausar H, Agrawal AK, Jeyabalan J, Kyakulaga AH, Munagala R, et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp Mol Pathol. 2016;101(1):12–21. https://doi.org/10.1016/j.yexmp.2016.05.013.
19. Munagala R, Aqil F, Jeyabalan J, Gupta RC. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 2016;371(1):48–61. https://doi.org/10.1016/j.canlet.2015.10.020.
20. Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013;3:2534. https://doi.org/10.1038/srep02534.
21. Kausar H, Munagala R, Bansal SS, Aqil F, Vadhanam MV, Gupta RC. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. Cancer Lett. 2013;332(1):35–45. https://doi.org/10.1016/j.canlet.2013.01.008.
22. Munagala R, Aqil F, Jeyabalan J, Gupta RC. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer. Cancer Lett. 2015;356(2 Pt B):536–46. https://doi.org/10.1016/j.canlet.2014.09.037.
23. Paul PK, Gupta SK, Bhatnagar S, Panguluri SK, Darnay BG, Choi Y, et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol. 2010;191(7):1395–411. https://doi.org/10.1083/jcb.201006098.
24. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32:1053-1064; https://doi.org/10.1016/j.biotechadv.2014.04.004.
25. Admyre C, Johansson SM, Qazi KR, Filen JJ, Lahesmaa R, Norman M, et al. Exosomes with immune modulatory features are present in human breast milk. J Immunol. 2007;179(3):1969–78.
26. Hata T, Murakami K, Nakatani H, Yamamoto Y, Matsuda T, Aoki N. Isolation of bovine milk-derived microvesicles carrying mRNAs and microRNAs. Biochem Biophys Res Commun. 2010;396(2):528–33. https://doi.org/10.1016/j.bbrc.2010.04.135S0006-291X(10)00830-2.
27. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18. https://doi.org/10.1021/mp700113r.
28. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomark Prev. 2002;11(1):105–11.
29. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–9. https://doi.org/10.1158/1078-0432.CCR-08-0024.
30. Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: physicochemical characterization and stability study. Eur J Pharm Sci. 2009;37(3–4):395–404. https://doi.org/10.1016/j.ejps.2009.03.009.
31. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37(3–4):223–30. https://doi.org/10.1016/j.ejps.2009.02.019.
32. Yadav VR, Suresh S, Devi K, Yadav S. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease. J Pharm Pharmacol. 2009;61(3):311–21. https://doi.org/10.1211/jpp/61.03.0005.
33. Chen C, Johnston TD, Jeon H, Gedaly R, McHugh PP, Burke TG, et al. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int J Pharm. 2009;366(1–2):133–9. https://doi.org/10.1016/j.ijpharm.2008.09.009.
34. Ranjan AP, Mukerjee A, Helson L, Gupta R, Vishwanatha JK. Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis. Anticancer Res. 2013;33(9):3603–9.
35. Nayak AP, Mills T, Norton I. Lipid based nanosystems for curcumin: past, present and future. Curr Pharm Des. 2016;22(27):4247–56.
36. Wang T, Ma X, Lei Y, Luo Y. Solid lipid nanoparticles coated with cross-linked polymeric double layer for oral delivery of curcumin. Colloids Surf B Biointerfaces. 2016;148:1–11. https://doi.org/10.1016/j.colsurfb.2016.08.047.
37. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330(1–2):155–63. https://doi.org/10.1016/j.ijpharm.2006.09.025.
38. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res. 2011;4(8):1158–71. https://doi.org/10.1158/1940-6207.CAPR-10-0006.
39. Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, Papworth GD, et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood. 2004;104(10):3257–66. https://doi.org/10.1182/blood-2004-03-0824.
40. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284(49):34211–22. https://doi.org/10.1074/jbc.M109.041152.
41. Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. J Cell Biochem. 2010;111(2):488–96. https://doi.org/10.1002/jcb.22733.
42. Tian T, Zhu YL, FH H, Wang YY, Huang NP, Xiao ZD. Dynamics of exosome internalization and trafficking. J Cell Physiol. 2013;228(7):1487–95. https://doi.org/10.1002/jcp.24304.
43. Agrawal AK, Aqil F, Jeyabalan J, Spencer WA, Beck J, Gachuki BW, et al. Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine. 2017;13(5):1627-1636;https://doi.org/10.1016/j.nano.2017.03.001.
44. Vashisht M, Rani P, Onteru SK, Singh D. Curcumin encapsulated in milk exosomes resists human digestion and possesses enhanced intestinal permeability in vitro. Appl Biochem Biotechnol. 2017; https://doi.org/10.1007/s12010-017-2478-4.
45. Liao Y, Du X, Li J, Lonnerdal B. Human milk exosomes and their microRNAs survive digestion in vitro and are taken up by human intestinal cells. Mol Nutr Food Res. 2017; https://doi.org/10.1002/mnfr.201700082.
46. Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010;38(1):215–24. https://doi.org/10.1093/nar/gkp857.
47. Mu J, Zhuang X, Wang Q, Jiang H, Deng ZB, Wang B, et al. Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. Mol Nutr Food Res. 2014;58(7):1561–73. https://doi.org/10.1002/mnfr.201300729.
48. Lei T, Srinivasan S, Tang Y, Manchanda R, Nagesetti A, Fernandez-Fernandez A, et al. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine. 2011;7(3):324–32. https://doi.org/10.1016/j.nano.2010.11.004.
49. Wang Q, Ren Y, Mu J, Egilmez NK, Zhuang X, Deng Z, et al. Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to deliver therapeutic agents to inflammatory tumor sites. Cancer Res. 2015;75(12):2520–9. https://doi.org/10.1158/0008-5472.CAN-14-3095.
50. Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. 2015;32(6):2003–14. https://doi.org/10.1007/s11095-014-1593-y.
51. Li C, Zhang Y, Su T, Feng L, Long Y, Chen Z. Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin. Int J Nanomedicine. 2012;7:5995–6002. https://doi.org/10.2147/IJN.S38043.
52. Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer’s disease Tg2576 mice. AAPS J. 2013;15(2):324–36. https://doi.org/10.1208/s12248-012-9444-4.
53. Li Z, Zheng Z, Ruan J, Li Z, Tzeng CM. Chronic inflammation links cancer and Parkinson’s disease. Front Aging Neurosci. 2016;8:126. https://doi.org/10.3389/fnagi.2016.00126.
54. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18(9):1606–14. https://doi.org/10.1038/mt.2010.105.
55. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014;46(1):2–18. https://doi.org/10.4143/crt.2014.46.1.2.
56. Jager R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. Nutr J. 2014;13:11. https://doi.org/10.1186/1475-2891-13-11.
57. Song Z, Lu Y, Zhang X, Wang H, Han J, Dong C. Novel curcumin-loaded human serum albumin nanoparticles surface functionalized with folate: characterization and in vitro/vivo evaluation. Drug Des Devel Ther. 2016;10:2643–9. https://doi.org/10.2147/DDDT.S112039.
58. Liskova K, Kelly AL, O'Brien N, Brodkorb A. Effect of denaturation of alpha-lactalbumin on the formation of BAMLET (bovine alpha-lactalbumin made lethal to tumor cells). J Agric Food Chem. 2010;58(7):4421–7. https://doi.org/10.1021/jf903901j.
59. Hoque M, Dave S, Gupta P, Saleemuddin M. Oleic acid may be the key contributor in the BAMLET-induced erythrocyte hemolysis and tumoricidal action. PLoS One. 2013;8(9):e68390. https://doi.org/10.1371/journal.pone.0068390.
60. Rath EM, Duff AP, Hakansson AP, Vacher CS, Liu GJ, Knott RB, et al. Structure and potential cellular targets of HAMLET-like anti-cancer compounds made from milk components. J Pharm Pharm Sci. 2015;18(4):773–824.
61. Rammer P, Groth-Pedersen L, Kirkegaard T, Daugaard M, Rytter A, Szyniarowski P, et al. BAMLET activates a lysosomal cell death program in cancer cells. Mol Cancer Ther. 2010;9(1):24–32. https://doi.org/10.1158/1535-7163.MCT-09-0559.